Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled trial of Xilonix in refractory symptomatic colorectal cancer
2014-000550-12Phase 3Completed
- Sponsor
- XBiotech Inc.
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Xilonix with Placebo (2 arms). Primary endpoint: Objective response rate. Started Apr 2014; status: completed.
02
Drugs
bermekimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2014-000550-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000550-12.